Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
01 Aug 2022 Results assessing effects of JAK1-Preferential Inhibitor Filgotinib on circulating biomarkers and whole blood Genes/Pathways using data from this study published in the Inflammatory Bowel Diseases
19 May 2020 Results, analysis of baseline correlation of whole blood transcriptome pathway activities with clinical disease indexes and circulating cytokines, published in Gastroenterology in conjunction with Digestive Disease Week 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com